• FDA Panel Votes Down Nektar Opioid Painkiller, Asks for More Data

    9 days ago - By Xconomy

    As the nation grapples with the ongoing opioid crisis, an FDA advisory panel on Tuesday unanimously voted against recommending approval of a Nektar Therapeutics painkiller that would add a new compound to the drug class-even though it was designed to reduce the risk of abuse. Some members of the panel, which was comprised mainly of physicians and pharmacists, said Nektar did not provide enough data to support its claims. Others expressed concern that an approval could send the message that the San Francisco company's drug is a “safer opioid.” Overall, panelists said that they want more...
    Read more ...